All sponsors

Zenas BioPharma (USA), LLC

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-34
RECRUITING2
READOUTS ≤12 MONTHS0
READOUT SLIPPED >6 MO20%

Delay Index: of 5 active trials registered more than a year ago, 1 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.4 months). See all sponsors →

Open Zenas BioPharma (USA), LLC on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Obexelimab
NCT06564311
P2Active, not recruitingRelapsing Multiple Sclerosis932025-08-28
INDIGO
NCT05662241
P3Active, not recruitingIgG4 Related Disease1942025-11-13
Obexelimab
NCT05786573
P3Active, not recruitingWarm Autoimmune Hemolytic Anemia1342026-06-30 (-6 mo)
SunStone
NCT06559163
P2Active, not recruitingSystemic Lupus Erythematosus1902026-09-23 (+11 mo)
Orelabrutinib
NCT07067463
P3RecruitingMultiple Sclerosis (MS) Primary Progressive7052030-06
Orelabrutinib
NCT07299019
P3RecruitingSecondary Progressive Multiple Sclerosis9902030-06